ERBB2 and breast carcinoma: This is particularly concerning for patients where antibody mediated therapy is part of their standard treatment of care e.g., anti-GD2 therapy for high risk neuroblastoma and trastuzumab for HER2+ breast cancer, and which works in part by promoting NK cell antibody dependent cellular cytotoxicity (ADCC) (8).